WOOD DALE, IL – PHC Corporation of North America (PHCNA), supplier of the PHCbi brand of preservation and growth products in North America and Latin America, has launched a next-generation… Read More
VANCOUVER, BC – Nimbus Synergies is pleased to announce its investment in EmergConnect, a pioneering digital health platform addressing Canada’s emergency department (ED) crisis. As part of a $1.75M CAD… Read More
QALSODY targets the root cause of SOD1-ALS, an ultra-rare and uniformly fatal neurodegenerative disease marked by motor neuron loss in the brain and spinal cord1 Biogen’s second rare disease therapy… Read More
Partnership marks AbbVie’s entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie’s global infrastructure for developing and… Read More
If approved, approximately 4,000 people with cystic fibrosis in the European Union will be eligible for a medicine that treats the underlying cause of their disease for the first time… Read More
